Camereyes

Company Overview

Snapshot

Founded in February 2015 by Udi Gordon, Barak Azmon, and David Rosenblatt, Camereyes operated with 1–10 employees. The company raised $950,000 across two funding rounds from VLX Ventures. In December 2015, Camereyes secured its initial funding, focusing on its deep-learning imaging platform.

Business overview

Camereyes developed an end-to-end solution for the detection and monitoring of diabetic retinopathy. Its core product, InSight, utilizes optics and deep-learning algorithms to provide a low-cost, automated solution, particularly in areas with limited access to professional eye care specialists. The company serves the healthcare industry, operating within the Digital Health and Medical Technologies sector, with a focus on diagnostics, ophthalmology, and chronic disease prevention.

Strategic signal

Camereyes ceased operations in January 2020, indicating a significant strategic shift and the conclusion of its efforts in developing deep-learning imaging platforms for diabetic retinopathy. This event signals to investors and innovation teams that the company's technology and business model did not achieve sustainable traction or market viability, leading to its discontinuation.

Company Intelligence Q&A

What is Camereyes' primary focus?

Camereyes developed a deep-learning imaging platform designed to prevent and monitor diabetic retinopathy through a simple, end-to-end solution.

When was Camereyes founded and by whom?

Camereyes was founded in February 2015 by Udi Gordon, Barak Azmon, and David Rosenblatt.

What was the total capital raised by Camereyes?

Camereyes raised a total of $950,000 across two funding rounds.

What is the status of Camereyes?

Camereyes is non-active and ceased to operate in January 2020.

Which investor participated in Camereyes' funding rounds?

VLX Ventures participated in Camereyes' funding rounds in December 2015 and April 2018.